A homogeneous bioluminescent inhibition immunoassay to detect anti-interferon gamma antibodies

• Published in: Clinical and experimental immunology 2024-11, Vol.218 (3), p.283-290
• Main Authors: Bradhurst, Peter, Stoyanov, Alex, Nithichanon, Arnone, Bundell, Christine, Urriola, Nicolás
• Format: Article
• Language: English
• Subjects: Adult; Aged; Female; Humans; Immunoassay - methods; Immunologic Deficiency Syndromes - diagnosis; Immunologic Deficiency Syndromes - immunology; Interferon-gamma - immunology; Luminescent Measurements - methods; Male; Middle Aged; Sensitivity and Specificity; Young Adult
• ISSN: 0009-9104; 1365-2249; 1365-2249
• DOI: 10.1093/cei/uxae055

Adult-onset immunodeficiency with antibodies to interferon-γ (AOID with AIGA) is a rare, acquired immunodeficiency causing susceptibility to disseminated non-tuberculous mycobacteria and other intracellular opportunistic infections. The diagnosis depends on demonstrating the presence of endogenous anti-interferon-γ antibodies (AIGA) that suppress Th1 cell-mediated immunity. Bioluminescent immunoassays are a newly emerging immunoassay format which utilize the action of bioluminescent enzymes on a substrate for specific analyte detection. In short, detecting antibodies are conjugated with a bioluminescent enzyme. The detecting antibodies bind the analyte of interest and produce light (luminescence) after addition of a substrate. The purpose of this study was to evaluate two newly developed bioluminescent immunoassays using Lumit® (Promega) technology as a diagnostic test for AOID with AIGA. Specific aims included the clinical validation of a new inhibition bioluminescent immunoassay technique to detect AIGA which block detection of interferon-γ (IFN-γ) in vitro and correlation of inhibition bioluminescent immunoassay results with AOID with AIGA disease status. Two bioluminescent inhibition immunoassays were developed. One which adapted an existing kit from Promega (Lumit® Human IFN-γ Immunoassay) and the other which was developed in house. Eighty-seven healthy controls and 48 patients with previously diagnosed AOID with AIGA were recruited and tested using these two methods. Results showed both bioluminescent inhibition immunoassays were able to clearly discriminate between AOID with AIGA patients and healthy controls. The mean inhibition percentage between patient groups correlated with disease activity. Both assays appeared to be more sensitive when compared to the existing inhibition ELISA.